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Appendices
Summary
Macrophage stimulating protein (MSP) is a blood plasma protein which is secreted mainly by the liver and exerts its effects by binding to the receptor tyrosine kinase Recepteur d'Origine Nantais (RON). The MSP-RON signaling has been intensively studied as a suppressor during toxic substance-induced inflammation, and is suggested to additionally have a role in the hepatic lipid and glucose metabolism. Given its participation in both inflammation and metabolic dysregulation, MSP emerges as a potential player in the field of metabolic syndrome (MetS). Yet, the knowledge on the regulatory role and treatment potential of MSP in MetS remains very limited. Within this thesis, the effects of MSP, as a novel plasma factor, in the field of MetS, specifically in the context of nonalcoholic steatohepatitis (NASH) and type 2 diabetes mellitus (T2DM), were investigated.
In Chapter 2, a detailed overview of MSP as a key player in inflammation and metabolic homeostasis is provided, and the rational for the central hypothesis is explained.
In Chapter 3, the regulatory role and the molecular mechanism of MSP in the development of inflammation and in lipid metabolism are investigated in in vitro models.
MSP was found to inhibit pro-inflammatory cytokine production and lipid accumulation in challenged hepatocytes. We further disclosed that those effects were mediated by the activation of the AMP-activated protein kinase (AMPK) signaling pathway. Furthermore, MSP also significantly suppressed inflammatory response in bone marrow-derived macrophage in an ex vivo model of NASH. Taken together, our data indicate that MSP acts as a key negative regulator of inflammation and of lipogenesis in vitro.
To further investigate the systemic therapeutic effects of MSP in NASH, low density lipoprotein receptor knock out (ldlr-/-) mice, an established NASH mouse model, were Previously, in cell studies and in animal models, MSP-RON signaling has been shown to suppress glucose production, but no relevant human data are available yet. In Chapter 5, possible associations of plasma MSP with metabolic profiles, as well as with glucose tolerance and incidence of T2DM were explored by using a prospective human cohortthe Cohort on Diabetes and Atherosclerosis Maastricht (CODAM). Our data showed that MSP was inversely associated with fasting glucose concentrations. However, higher baseline MSP concentrations did not appear to protect against the development T2DM Summary Appendices over the 7-year follow-up period. Furthermore, MSP was prominently and positively associated with apoB-containing lipoproteins. These findings provide further evidence to the relevance of MSP in the regulation of glucose and lipid metabolism.
Finally, we brought together the results from the individual experimental chapters in
Chapter 6, and discussed the clinical potential of MSP in both NASH and T2DM. In addition, an emerging link regarding MSP and sex hormones is formulated. Furthermore, as an interesting association between MSP and low density lipoprotein (LDL) cholesterol was hit upon in the studies of this thesis, possible mechanism about how MSP interacts with LDL cholesterol are discussed. Finally, future perspectives are given as to how the presented work could be followed up.
In summary, the present thesis offers new insights into understanding the regulation and (patho) physiological roles of MSP, as a novel plasma factor, in the field of MetS, and presents perspectives for future research. 
